BACKGROUND: Although the performance of immunocytology has been established in the surveillance of patients with urothelial carcinoma of the bladder (UCB), its value in the initial detection of UCB in patients with painless hematuria remains unclear. OBJECTIVE: To determine whether immunocytology improves our ability to predict the likelihood of UCB in patients with painless hematuria. Further, to test the clinical benefit of immunocytology in this setting using decision curve analysis. DESIGN, SETTING, AND PARTICIPANTS: The subjects were 1182 consecutive patients without a history of UCB presenting with painless hematuria and were enrolled at three centres. INTERVENTION: All patients underwent upper-tract imaging, cystourethroscopy, voided urine cytology, and immunocytology analysis. Bladder tumors were biopsied and histologically confirmed as UCB. MEASUREMENTS: Multivariable regression models were developed. Area under the curve was measured and compared using the DeLong test. A nomogram was constructed from the full multivariable model. Decision curve analysis was performed to evaluate the clinical benefit associated with use of the multivariable models including immunocytology. RESULTS AND LIMITATIONS: Immunocytology had the largest contribution to a multivariable model for the prediction of UCB (odds ratio: 18.3; p<0.0001), which achieved a 90.8% predictive accuracy. Decision curve analysis revealed that models incorporating immunocytology achieved the highest net benefit at all threshold probabilities. CONCLUSIONS: Immunocytology is a strong predictor of the presence of UCB in patients who present with painless hematuria. Incorporation of immunocytology into predictive models improves diagnostic accuracy by a statistically and clinically significant margin. The use of immunocytology in the diagnostic workup of patients with hematuria appears promising and should be further evaluated.
BACKGROUND: Although the performance of immunocytology has been established in the surveillance of patients with urothelial carcinoma of the bladder (UCB), its value in the initial detection of UCB in patients with painless hematuria remains unclear. OBJECTIVE: To determine whether immunocytology improves our ability to predict the likelihood of UCB in patients with painless hematuria. Further, to test the clinical benefit of immunocytology in this setting using decision curve analysis. DESIGN, SETTING, AND PARTICIPANTS: The subjects were 1182 consecutive patients without a history of UCB presenting with painless hematuria and were enrolled at three centres. INTERVENTION: All patients underwent upper-tract imaging, cystourethroscopy, voided urine cytology, and immunocytology analysis. Bladder tumors were biopsied and histologically confirmed as UCB. MEASUREMENTS: Multivariable regression models were developed. Area under the curve was measured and compared using the DeLong test. A nomogram was constructed from the full multivariable model. Decision curve analysis was performed to evaluate the clinical benefit associated with use of the multivariable models including immunocytology. RESULTS AND LIMITATIONS: Immunocytology had the largest contribution to a multivariable model for the prediction of UCB (odds ratio: 18.3; p<0.0001), which achieved a 90.8% predictive accuracy. Decision curve analysis revealed that models incorporating immunocytology achieved the highest net benefit at all threshold probabilities. CONCLUSIONS: Immunocytology is a strong predictor of the presence of UCB in patients who present with painless hematuria. Incorporation of immunocytology into predictive models improves diagnostic accuracy by a statistically and clinically significant margin. The use of immunocytology in the diagnostic workup of patients with hematuria appears promising and should be further evaluated.
Authors: E W Steyerberg; F E Harrell; G J Borsboom; M J Eijkemans; Y Vergouwe; J D Habbema Journal: J Clin Epidemiol Date: 2001-08 Impact factor: 6.437
Authors: Phillip L Ross; Claudia Gerigk; Mithat Gonen; Ofer Yossepowitch; Ilias Cagiannos; Pramod C Sogani; Peter T Scardino; Michael W Kattan Journal: Semin Urol Oncol Date: 2002-05
Authors: B J Schmitz-Dräger; L-A Tirsar; C Schmitz-Dräger; J Dörsam; Z Mellan; E Bismarck; T Ebert Journal: World J Urol Date: 2007-12-12 Impact factor: 4.226
Authors: Marko Babjuk; Willem Oosterlinck; Richard Sylvester; Eero Kaasinen; Andreas Böhle; Juan Palou-Redorta Journal: Eur Urol Date: 2008-04-30 Impact factor: 20.096
Authors: Maria Frantzi; Agnieszka Latosinska; Leif Flühe; Marie C Hupe; Elena Critselis; Mario W Kramer; Axel S Merseburger; Harald Mischak; Antonia Vlahou Journal: Nat Rev Urol Date: 2015-05-26 Impact factor: 14.432
Authors: Christian Daniel Fankhauser; Sharon Waisbrod; Cindy Fierz; Anton S Becker; Benedikt Kranzbühler; Daniel Eberli; Tullio Sulser; Hugh Mostafid; Thomas Hermanns Journal: World J Urol Date: 2020-04-02 Impact factor: 4.226
Authors: Alessandro Sciarra; Giovanni Di Lascio; Francesco Del Giudice; Pier Paolo Leoncini; Stefano Salciccia; Alessandro Gentilucci; Angelo Porreca; Benjamin I Chung; Giovanni Di Pierro; Gian Maria Busetto; Ettore De Berardinis; Martina Maggi Journal: Curr Urol Date: 2021-03-29
Authors: Hannah Harrison; Juliet A Usher-Smith; Lanxin Li; Lydia Roberts; Zhiyuan Lin; Rachel E Thompson; Sabrina H Rossi; Grant D Stewart; Fiona M Walter; Simon Griffin; Yin Zhou Journal: Br J Gen Pract Date: 2021-12-31 Impact factor: 5.386
Authors: Willemien Beukers; Raju Kandimalla; Diandra van Houwelingen; Hrvoje Kovacic; Jie-Fen D Chin; Hester F Lingsma; Lars Dyrskjot; Ellen C Zwarthoff Journal: PLoS One Date: 2013-10-15 Impact factor: 3.240
Authors: Francesco Soria; Michael J Droller; Yair Lotan; Paolo Gontero; David D'Andrea; Kilian M Gust; Morgan Rouprêt; Marek Babjuk; Joan Palou; Shahrokh F Shariat Journal: World J Urol Date: 2018-06-21 Impact factor: 4.226
Authors: Francesco Soria; Laura-Maria Krabbe; Tilman Todenhöfer; Jakub Dobruch; Anirban P Mitra; Brant A Inman; Kilian M Gust; Yair Lotan; Shahrokh F Shariat Journal: World J Urol Date: 2018-09-26 Impact factor: 4.226